[email protected] These authors have contributed equally to this work This article was submitted to Microbiotechnology, a section of the journal Frontiers in Microbiology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
10.1111/1346-8138.15042 J Dermatol
Buyer reorder rates provide insight into product performance and supplier reliability post-purchase
Disclosures: Fajuan Rui: Nothing to Disclose, Yee Hui Yeo: Nothing to Disclose, Wenjing Ni: Nothing to Disclose, Liang Xu: Nothing to Disclose, Qi Zheng: Nothing to Disclose, Youwen Tan: Nothing to Disclose, Qing-Lei Zeng: Nothing to Disclose, Ming-Hua Zheng: Nothing to Disclose, Zebao He: Nothing to Disclose, Yuanwang Qiu: Nothing to Disclose, chuanwu zhu: Nothing to Disclose, Chao Wu: Nothing to Disclose, Yuemin Nan: Nothing to Disclose, Junping Shi: Nothing to Disclose, Jie Li: Nothing to Disclose 427 CHARACTERIZATION OF HDV RNA AND HBSAG DURING PEGYLATED INTERFERON-ALPHA AND RITONAVIR-BOOSTED LONAFARNIB COMBINATION THERAPY: THE D-LIVR STUDY Leeor Hershkovich 1 Harel Dahari 1 Scott Cotler 2 Theo Heller 3 Christopher Koh 3 Jeffrey Glenn 4 Tarik Asselah 5 Saeed Hamid 6 Ohad Etzion 7 , 1 Loyola University Chicago, 2 Loyola University Health System, 3 Liver Disease Branch, NIDDK, NIH, 4 Stanford School of Medicine, 5 Hpital Beaujon, 6 Aga Khan University, 7 Soroka University Medical Center Background: Understanding of the kinetic profiles of hepatitis D virus (HDV) and hepatitis B surface antigen (HBsAg) during pegylated-interferon--2a (pegIFN) and ritonavir-boosted lonafarnib (LNF) therapy is lacking
Most of these formulations contain ethinyl estradiol (EE) as the synthetic estrogen in combination with various progestins
The range made available by us is processed & formulated using high-grade ingredients that are sourced from most trusted and reliable vendors of market with the aid of our sourcing agents
